article
Rapid Cardiovascular Response to Belzutifan in HIF2A -Mediated Paraganglioma
Hussam R Alkaissia b, Matthew A. Nazaric d, Katerina Hadrava Vanovac d, Ondřej Uherc d, Catherine M. Gordonc d, Sara K Talvacchioc d, Nina Diachenkoe f, O.M. Mukviche f, Herui Wangg h, John W. Glodg h, Zhengping Zhuangg h, Karel Pacáki j
- a<!--eXtyles-to-JATS: Please confirm that content of institution is an institution.-->National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
- bNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
- c<!--eXtyles-to-JATS: Please confirm that content of institution is an institution.-->National Institutes of Health, Bethesda, MD
- dNational Institutes of Health, Bethesda, MD
- e<!--eXtyles-to-JATS: Please confirm that content of institution is an institution.-->Institute of Pediatrics, Obstetrics, and Gynecology, Kyiv, Ukraine
- fInstitute of Pediatrics, Obstetrics, and Gynecology, Kyiv, Ukraine
- g<!--eXtyles-to-JATS: Please confirm that content of institution is an institution.-->National Cancer Institute, Bethesda, MD
- hNational Cancer Institute, Bethesda, MD
- i<!--eXtyles-to-JATS: Please confirm that content of institution is an institution.-->Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD
Looking for the full paper…
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Many patients with pheochromocytoma and paraganglioma have hypertension from tumor-derived catecholamines. The HIF-2α inhibitor belzutifan rapidly reduced blood pressure and excess catecholamine levels.